– USA, NY – Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Cynthia Schwalm to its Board of Directors. Ms. Schwalm has extensive pharmaceutical industry experience, having held management roles at Johnson & Johnson, Amgen and Eisai, and most recently served as President and CEO of Ipsen North America.
“Cynthia is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Kadmon,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “Cynthia has a demonstrated track record of cultivating successful businesses and implementing tactical changes to drive transformative growth. We are pleased to welcome Cynthia and believe that her fresh perspectives, combined with the experience of our Board and senior management team, will augment Kadmon’s capabilities, board leadership and guidance to bring promising new therapies to market.”
About Cynthia Schwalm
Ms. Schwalm currently serves as the Owner of EIR Advisory LLC, a healthcare-focused strategic partnership and investment company, and as a member of the board of directors at G1 Therapeutics and Caladrius Biosciences. Ms. Schwalm served as President and CEO of Ipsen Biopharmaceuticals North America from 2014 through 2017. Prior to joining Ipsen, Ms. Schwalm spent two years in various acting COO and C-suite consulting roles for emerging biotechnology and pharmaceutical companies. Prior to these roles, Ms. Schwalm served as President of Eisai Pharmaceuticals from 2008 to 2010, and as Executive Director from 2003 to 2005 and Vice President from 2005 to 2008 at Amgen, where she ran their oncology business. From 1985 to 2003, Ms. Schwalm held multiple commercial roles, domestically and internationally, at Johnson & Johnson. Ms. Schwalm started her career in oncology and critical care nursing. Ms. Schwalm received her MBA from the Wharton School of the University of Pennsylvania and her B.S.N. from the University of Delaware. Ms. Schwalm is a member of the National Association of Corporate Directors.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative product candidates for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases.
For more information : https://www.kadmon.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.